EYE — National Vision Holdings, Inc. · 2026-09-05 · Verdict: WATCH · Conviction 2
Price $16.74 (screen close 2026-09-05; no live quotes) · Mkt cap $1.32B · EV $1.53B · EV/EBIT 25.9x stale GAAP, ~6.9x guided adj EBITDA · FCF yield 5.6% · Net debt $(201.7)M · ADV $44.7M Sources: 10-K 2026-03-04 for FY2025 ended 2026-01-03 (Items 1, 1A, 7), 10-Q 2026-08-13 (Q2 ended 2026-07-04), DEF 14A 2026-05-04, 8-Ks 2026-05-13, 2026-06-03, 2026-06-22, 2026-08-12, Form 4s (12m). No transcript in the bundle.
1. What the business actually does
The value segment of US optical retail: 1,281 stores at 2026-07-04, of which 1,069 are America's Best, 122 Eyeglass World and 90 Vista Optical host locations on military bases and inside Fred Meyer (10-Q, MD&A). It sells eye exams, eyeglasses and contact lenses, routing lens orders through four company labs plus one outsourced international facility, which is the scale advantage. Exams come from 2,367 optometrists, only 635 directly employed, with telehealth in over 800 America's Best stores to work around a shortage the 10-K says persisted through 2025 (Items 1, 1A). The Eyecare Club, about 1.3 million members paying up front for three-year memberships, is the source of the unearned revenue that distorts quarters (10-K, Item 1).
2. Why it is mispriced — the edge case
There is none I can identify, so the verdict is capped at WATCH. The screen's signal is a stale-data artifact: 25.9x EV/EBIT charges CY2025 GAAP operating income of $58.8M, struck after $23.7M of stock compensation, $6.4M of ERP and CRM cost and $2.0M of impairment (10-K, Item 7), against today's enterprise value; on the guided year the same $1.53B is about 6.9x adjusted EBITDA. But nothing is forcing anyone out. BlackRock owns 14.4% and Wellington 7.3%; Vanguard's 13G/A reporting zero shares on 2026-03-27 is an internal realignment, not selling (DEF 14A). Volume is $44.7M a day on a $1.32B cap and the June annual meeting was routine. Form 4 tax-withholding prices put the stock at $22.04 on 2026-07-31, $18.92 on 2026-08-19 and $16.82 on 2026-09-02, so the market marked it down about 24% after the August guidance raise, not before it. That is a judgment on the quality of the quarter, and the numbers below make it defensible.
3. Unit economics and growth
The margin gain is real: adjusted operating margin went 3.1% in FY2023 to 3.6% in FY2024 to 5.2% in FY2025 on revenue of $1,987.5M, up 9.0% (10-K, Item 7), and H1 2026 adjusted operating income rose 33.7% to $87.0M at 8.3% (8-K, 2026-08-12). Three corrections. First, $10.0M of that H1 figure is the net change in margin on unearned revenue, worth $0.09 of adjusted EPS; underlying growth was 18.3%. Second, it came from cost, not the top line: Q2 costs applicable to revenue rose 60bp to 41.8% on a mix shift to higher-value product, while SG&A fell 200bp to 48.8% on "lower associate-related expenses, including variable incentive compensation, and lower advertising expense" (8-K, 2026-08-12). Cutting advertising is a strange lever when traffic is the problem. Third, adjusted operating income adds back $23.7M of FY2025 stock compensation and $13.4M in H1, a real cost worth 1.3% of revenue.
The decelerating line is adjusted comparable store sales: 6.0% FY2025, 4.5% Q1 2026, 2.2% Q2, each "due to higher average ticket and continued strength in the managed care cohort, partially offset by lower self-pay customer traffic" (10-K Item 7; 8-Ks 2026-05-13, 2026-08-12). Growth is price and mix against falling units, and the 10-K concedes that as managed care, 42% of revenue, "continues to grow closer to overall industry penetration levels, we expect our associated revenue growth rate to slow over time" (Item 1A). H1 operating cash flow fell 19% to $69.8M on a $57.4M working capital swing (10-Q), against FY2025 free cash flow of $73.5M.
4. Balance sheet and capital allocation
Clean: total debt $237.7M against $36.0M cash and an undrawn $300M revolver, so net debt of $201.7M is about 0.9x guided adjusted EBITDA, all covenants met (10-Q). The only real maturity is a $211.1M term loan balloon in 2028; undiscounted operating lease payments of $529.7M are the larger obligation and already sit inside the margin (10-K, Item 7). Capital allocation is the weak part. The board authorized $50M in February 2024, repurchased nothing in FY2024 or FY2025, and let it expire unused on 2026-01-03 while the stock fell. A new $50M followed on 2026-03-02, of which $20M for 1.2M shares was spent in Q2, yet weighted diluted shares still rose from 79.7M to 81.0M year over year in H1 (10-Q). No insider bought in the open market in twelve months at any price (form4_summary; 12 of 39 filings parsed). The proxy shows 2025 incentives funding at 196.6% of target on a "STIP AOI" of $134.5M, a bonus measure $32M above the $102.5M reported to shareholders (DEF 14A, 2026).
5. Management: said versus did
Credible so far. The 2026 outlook was reiterated 2026-05-13, confirmed 2026-06-03 with the disclosure that the e-commerce replatform had temporarily disrupted traffic and Q2 comps were tracking "in the low-single-digit range," which is what arrived, then raised 2026-08-12 to adjusted operating income of $119-139M from $107-133M, while cutting the comp guide's top end to 5.0% from 6.0%. Against $87.0M already earned, the raise implies H2 adjusted operating income of $32-52M versus $37.4M in H2 2025: about +12% at the midpoint after +33.7% in H1, with the low end below last year. The team is new, Alex Wilkes CEO from 2025-08-01 and the CFO seat changing twice in 2025 (DEF 14A).
6. Valuation
Base (50%): revenue grows about 3%, adjusted operating margin improves from the guided 6.3% toward 7.0% by 2029, stock compensation near $30M, capex near $80M against D&A near $100M, free cash flow reaching about $104M; at a 9% discount and 2.5% terminal growth, roughly $16.15. Bear (25%): traffic loss overwhelms ticket, comps go flat, margin reverts to FY2025's 5.0% on $2.0B of revenue, free cash flow $69M with no growth, about $7.15. Bull (25%): revenue reaches $2.4B by 2029 at an 8.5% adjusted margin, free cash flow $130M, about $22.30. Probability-weighted $15.45, roughly 8% below price. Reverse DCF: at $16.74 the $1.53B enterprise value against normalized free cash flow to the firm of about $89M (guided adjusted operating income less stock compensation, taxed at 30%, plus D&A less capex) implies roughly 3.2% perpetual growth at a 9% discount rate, which is what a value optical retailer with declining unit traffic would have to compound at forever.
7. Catalysts and timeline
Q3 2026 in November is the decisive print, arriving with the replatform disruption behind the company and the back-half marketing spent, so it shows whether self-pay traffic stabilizes; the $32-52M H2 range is wide enough that Q3 either confirms or breaks the raise. Longer dated: refinancing ahead of the 2028 balloon, the stated reacceleration to about 60 new stores a year from 2028, and any refund of duties paid under the tariff regime struck down by the Supreme Court (10-K, Item 1A).
8. Risks and pre-registered kill criteria
- Adjusted comparable store sales below 2.0% in any quarter, or self-pay traffic still described as declining in both Q3 and Q4 2026.
- Costs applicable to revenue above 41.5% of net revenue for two consecutive quarters. Q2's 41.8% trips this if Q3 repeats, meaning the premium mix is buying revenue with gross margin.
- Fiscal 2026 adjusted operating income below $119M, or the guide cut at Q3.
- Fiscal 2026 operating cash flow below $120M against FY2025's $146.3M, confirming the working capital build is structural rather than timing. Material but not pre-registered: optometrist wage inflation, payor concentration inside that 42% of revenue, and tariffs on Chinese frames, sized at under 10% of costs applicable to revenue (10-K, Item 1A).
9. Verdict and one-paragraph summary
WATCH, conviction 2. The turnaround is real and the screen's 25.9x EV/EBIT is a stale-data artifact of charging CY2025 GAAP operating income against today's enterprise value; corrected, the same $1.53B is about 6.9x guided adjusted EBITDA on under one turn of leverage. But there is no edge case to underwrite, no forced seller, spin or index event, just $44.7M of daily volume and BlackRock at 14.4%, so the 43% fall from the high is a verdict rather than a dislocation, and it looks roughly right: adjusted comps decelerated from 6.0% to 4.5% to 2.2% with self-pay traffic falling every period, $10.0M of the $87.0M of H1 adjusted operating income is unearned revenue timing, Q2's margin gain came entirely from cutting advertising and incentive pay while gross margin fell 60bp, and the raised guide still implies H2 profit up only about 12% at the midpoint with a low end below last year. Capital allocation says the same: a $50M authorization expired completely unused through a two-year decline, the new $20M of buying barely offsets dilution, and no insider has bought in the open market in twelve months at any price. Probability-weighted value of $15.45 is 8% below the $16.74 price, which already implies 3.2% perpetual growth.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.